STATUTORY INSTRUMENTS

2019 No. 775

The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019

PART 4

Amendment of Part 4 (requirement for authorisation)

Amendment of regulation 46 (requirement for authorisation)

- **45.**—(1) Regulation 46 is amended as follows.
- (2) In paragraph (2)—
 - (a) in sub-paragraph (a), before "marketing authorisation", insert "UK";
- I^{F1}(b) after sub-paragraph (a) insert—
 - "(aa) an EU marketing authorisation;".]
- (3) In paragraph (3), before "European Economic Area" insert "United Kingdom or the".
- (4) In paragraph (6)—
- [F2(a) after "in force for the product" insert "in the country in which the product is intended to be sold or supplied, or offered for sale or supply";
 - (b) in sub-paragraph (a), before "marketing authorisation", insert "UK"; and
 - (c) after sub-paragraph (a) insert—
 - "(aa) an EU marketing authorisation;".]
- (6) In paragraph (9), before "European Economic Area" insert "United Kingdom or the".
- (7) In paragraph (11)(a), before "European Economic Area" insert "United Kingdom or the".

Textual Amendments

- F1 Reg. 45(2)(b) substituted for reg. 45(2)(b)(c) (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 33(a)
- F2 Reg. 45(4)(a)-(c) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 33(b)
- F3 Reg. 45(5) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 33(c)

Commencement Information

I1 Reg. 45 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Changes to legislation:
There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019, Section 45.